Skip to main content
Clinical Trials/NCT02787668
NCT02787668
Completed
Not Applicable

A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity

University of Alabama at Birmingham1 site in 1 country27 target enrollmentMay 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-alcoholic Fatty Liver Disease
Sponsor
University of Alabama at Birmingham
Enrollment
27
Locations
1
Primary Endpoint
Change in hepatic lipid assessed via magnetic resonance imaging (MRI and magnetic resonance spectroscopy (MRS).
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to determine the effects of a low carbohydrate diet vs a low fat diet on improvement in aminotransferases, hepatic fat infiltration, markers of inflammation, insulin resistance, and body composition in obese adolescents with non-alcoholic fatty liver disease (NAFLD).

Detailed Description

NAFLD is the most common form of liver disease in children in the United States. Currently, there is no treatment for NAFLD. In adults, weight loss through caloric restriction is commonly recommended to improve fatty liver. Weight loss is particularly difficult for children to achieve and significant caloric restriction may not be a prudent recommendation in developing children and adolescents. Because of this difficulty with weight loss in children, many children go on to develop cirrhosis and eventually undergo liver transplant. Data on the effectiveness of diet to reverse fatty liver and prevent progression to cirrhosis in children is urgently needed. To date, no studies have been done examining how changes in diet composition without intentional caloric restriction influences NAFLD in children. Data from previous studies in adults support the hypothesis that consumption of lower-CHO, higher-fat food sources rich in high-quality proteins and essential fatty acids has beneficial effects on metabolic health in adults without restricting calories. This study aims to test the hypothesis that a low CHO higher- fat diet will induce rapid reversal of fatty liver while also depleting of total and abdominal adiposity, preserving lean mass, and reducing inflammation in adolescents with obesity and NAFLD.

Registry
clinicaltrials.gov
Start Date
May 2016
End Date
April 2018
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amy Miskimon Goss

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • Overweight/obese (BMI over the 85th percentile) male and female adolescents (age range 10-17) with elevated serum aminotransferase levels, diffusely echogenic liver via ultrasound suggestive of fatty liver, and/or prior diagnosis of NAFLD. Participant eligibility will depend on the ability of one parent to attend the initial diet instruction and individual counseling sessions with the registered dietitian during week 2, 4 and 6 of the diet intervention.

Exclusion Criteria

  • Presence of hepatic virus infections (HCV RNA-polymerase chain reaction negative; hepatitis A, B, C, D, E, and G; cytomegalovirus; and Epstein-Barr virus), alcohol consumption, history of parenteral nutrition, and use of drugs known to induce steatosis (for example, valproate, amiodarone, or prednisone) or to affect body weight and carbohydrate metabolism. Autoimmune liver disease, metabolic liver disease, and Wilson's disease will be ruled out by the participants physician prior to enrollment in the study.

Outcomes

Primary Outcomes

Change in hepatic lipid assessed via magnetic resonance imaging (MRI and magnetic resonance spectroscopy (MRS).

Time Frame: 8 weeks after baseline

Secondary Outcomes

  • Change in body composition via dual-energy X-ray absorptiometry (DXA).(8 weeks after baseline)
  • Change in liver enzymes via fasting blood draw(At baseline and weeks 2, 4, and 8.)
  • Change in fasting glucose via blood draw(At baseline and weeks 2, 4, and 8.)
  • Change in fasting insulin via blood draw(At baseline and weeks 2, 4, and 8.)

Study Sites (1)

Loading locations...

Similar Trials